Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 464 Melanoma 300 Squamous Cell Carcinoma of Head and Neck 234 Parkinson Disease 4, Autosomal Dominant Lewy Body 189 Neoplasms 185 Triple Negative Breast Neoplasms 163 Breast Neoplasms 162 Neoplasm Metastasis 157 Lung Neoplasms 147 Colorectal Neoplasms 142 Carcinoma, Renal Cell 132 Head and Neck Neoplasms 123 Stomach Neoplasms 104 Ovarian Neoplasms 101 Carcinoma, Transitional Cell 92 Urinary Bladder Neoplasms 81 Pancreatic Neoplasms 81 Endometrial Neoplasms 74 Carcinoma, Hepatocellular 74 Uterine Cervical Neoplasms 63 Esophageal Neoplasms 57 Recurrence 52 Prostatic Neoplasms 49 Sarcoma 43 Carcinoma 42 Glioblastoma 40 Small Cell Lung Carcinoma 39 Carcinoma, Squamous Cell 39 Hodgkin Disease 36 Cholangiocarcinoma 35

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Bladder Carcinoma × pembrolizumab × Clear all

NCT02736266 2023-07-18

PURE-01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡